Back to results

CompletedPhase 3

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

NCT03436693

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research site

Aichi, Japan

+25 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2018-02-15
Enrollment: 308 participants
Sponsor: Tanabe Pharma Corporation
Purpose: treatment

Locations (26)

Research siteAichi, Japan
Research siteChiba, Japan
Research siteFukuoka, Japan
Research siteFukushima, Japan
Research siteGunma, Japan
Research siteHiroshima, Japan
Research siteHokkaido, Japan
Research siteHyōgo, Japan
Research siteIbaraki, Japan
Research siteKagawa, Japan
Research siteKagoshima, Japan
Research siteKanagawa, Japan
Research siteKumamoto, Japan
Research siteMie, Japan
Research siteNagano, Japan
Research siteNagasaki, Japan
Research siteOkinawa, Japan
Research siteOsaka, Japan
Research siteŌita, Japan
Research siteSaitama, Japan
Research siteShizuoka, Japan
Research siteTochigi, Japan
Research siteTokyo, Japan
Research siteWakayama, Japan
Research siteYamagata, Japan
Research siteYamaguchi, Japan

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy — TrialFind